Clinical Trial Update: Efficacy and Safety of Pentamidine (7mg/kg) for Patients With Cutaneous Leishmaniasis Caused by L. Guyanensis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy and safety of pentamidine at 7 mg/kg for cutaneous leishmaniasis caused by Leishmania guyanensis; the study status is comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Leishmaniasis

Drugs mentioned

• Pentamidine (pentamidine)

Snippet

Sponsor: Fundação de Medicina Tropical Dr. Heitor Vieira Dourado | Conditions: Cutaneous Leishmaniases | Phase 2 | Status: COMPLETED